11.4.2024 21:07:01 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state
Reference is made to the stock exchange announcement of Thor Medical ASA (the
"Company") today regarding the completion of the annual general meeting. For the
sake of good order, it is noted that a minor error has been detected in the
minutes, where it was stated that the members of the nomination committee shall
receive fees from taking office until the annual general meeting in 2024. This
should be 2025, as suggested by the nomination committee and as resolved by the
annual general meeting of the Company.
Attached are updated minutes to reflect the resolution made by the ordinary
general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
CONTACTS
* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visitwww.thormedical.no - https://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3018/4300/Download%20announcement
%20as%20PDF.pdf
Minutes from ordinary general meeting 2024.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3018/4299/Minutes%20from%20ordina
ry%20general%20meeting%202024.pdf